AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation  Summit 

Stockholm, Sweden, April 4 , 2024

AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel  contractile agents to treat patients with heart failure, announced today that it has been selected  as one of 11 finalists to present at the inaugural J.P. Morgan Asset Management: Life Sciences  Innovation Summit. The summit will take place on May 14-15, 2024 at the Cleveland Clinic Abu  Dhabi during the Abu Dhabi Global Healthcare Week. The aim is to bring together innovators,  investors, and industry leaders to explore the latest advancements and trends shaping the  future of healthcare. The finalists were selected from over 150 highly qualified applications  submitted from around the globe and with a diverse range of companies and research  institutions developing innovative therapeutic solutions. AnaCardio will be represented at the  summit by CEO Patrik Strömberg. 

“It is an honor for AnaCardio to be represented at this prestigious event. To be selected as a  finalist amongst these highly innovative companies, which all have the potential to develop transformative treatments, is a great recognition of our efforts to bring our novel therapy to  patients with heart failure.”, commented Patrik Strömberg. 

More information about the summit and the selected finalists can be found here. 

About AnaCardio 

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel  drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska  Institutet showing improved contractility of the heart muscle through a unique and differentiated  mechanism. Its lead program AC01 is an oral ghrelin peptidomimetic small-molecule is being developed  as a contractile agent in heart failure patients.  

You can find more information about AnaCardio at  

For further information, please contact 

Patrik Strömberg, CEO 

Telephone: +46 704 156 159 


Share this article on social media

Rekommenderade artiklar